Table 1.
Baseline characteristics of the TRILOGY-ACS study populations.
| TRILOGY-ACS | Subgroup with PRU and blood samples from TRILOGY-ACS | Targeted Analysis Cohort | Nested Case-Control Cohort | |
|---|---|---|---|---|
| Demographic Information | N = 9326 | N = 1391 | N = 878 | N = 153 |
| Age (years) | 65.7 (59.0, 74.0) | 66.0 (59.0, 74.0) | 67.0 (59.0, 73.0) | 70.0 (64.0, 76.0) |
| Male, N (%) | 5676 (60.9%) | 859 (61.8%) | 541 (61.6%) | 106 (69.3%) |
| White, N (%) | 6276 (67.3%) | 1141 (82.0%) | 725 (82.6%) | 127 (83.0%) |
| BMI, kg m−2 | 27.1 (24.2, 30.5) | 27.7 (25.0, 31.1) | 27.6 (25.1, 31.1) | 27.8 (24.8, 31.1) |
| Cardiovascular Risk Factors | 2840 (31.7%) | 438 (32.4%) | 221 (32.1%) | 221 (32.1%) |
| Cr Cl (ml/min) | 73.0 (54.0, 96.5) | 75.9 (56.0, 100) | 75.4 (56.2, 100) | 65.9 (51.1, 90.5) |
| Current or recent smoker, N (%) | 1715 (18.6%) | 258 (18.8%) | 155 (17.8%) | 31 (20.7%) |
| Diabetes mellitus, N (%) | 3539 (38.0%) | 500 (36.0%) | 313 (35.7%) | 56 (36.8%) |
| GRACE risk score | 121.0 (105.0, 139.0) | 124.0 (106.0, 144.0) | 124.0 (108.0, 143.3) | 133.0 (116.5, 154.0) |
| Prior MI, N (%) | 3987 (43.1%) | 652 (47.1%) | 392 (44.9%) | 72 (47.4%) |
| Concomitant Medications | ||||
| Aspirin, N (%) | 8572 (91.9%) | 1280 (92.0%) | 817 (93.1%) | 144 (94.1%) |
| Beta blocker, N (%) | 7251 (77.8%) | 1118 (80.4%) | 705 (80.3%) | 121 (79.1%) |
| Statin, N (%) | 7776 (83.4%) | 1164 (83.7%) | 746 (85.0%) | 134 (87.6%) |
| Assigned to prasugrel arm, N (%) | 4663 (50.0%) | 690 (49.6%) | 418 (47.6%) | 74 (48.4%) |
| Index NSTEMI, N (%) | 6520 (69.9%) | 938 (67.4%) | 591 (67.3%) | 135 (88.2%) |
| Index Unstable angina, N (%) | 2302 (24.7%) | 366 (26.3%) | 231 (26.3%) | 14 (9.2%) |
| CVD/MI/Stroke within 1 yr. of index event, N (%) | 954 (10.2%) | 156 (11.2%) | 81 (9.2%) | 77 (50.3%) |
Continuous variables are presented as median (25th and 75th percentile) and categorical variables are presented as percentages.